share_log

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Benzinga ·  May 13 16:20
Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment